

Yutaka Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/549261/publications.pdf>

Version: 2024-02-01

68
papers

1,434
citations

257450
24
h-index

345221
36
g-index

73
all docs

73
docs citations

73
times ranked

2483
citing authors

#	ARTICLE	IF	CITATIONS
1	High density of <sc>CD</sc>204â€positive macrophages predicts worse clinical prognosis in patients with breast cancer. Cancer Science, 2017, 108, 1693-1700.	3.9	83
2	Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Research and Treatment, 2019, 173, 123-133.	2.5	77
3	Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer, 2010, 17, 118-124.	2.9	67
4	Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. OncoTargets and Therapy, 2011, 4, 123.	2.0	67
5	Prognostic role of <i><sc>PIK</sc>3<sc>CA</sc></i> mutations of cellâ€free <sc>DNA</sc> in earlyâ€stage triple negative breast cancer. Cancer Science, 2015, 106, 1582-1589.	3.9	58
6	Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Translational Research, 2015, 166, 540-553.e2.	5.0	55
7	Evaluating the 21-gene assay Recurrence ScoreÂ® as a predictor of clinical response to 24Âweeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International Journal of Clinical Oncology, 2014, 19, 607-613.	2.2	54
8	The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0166680.	2.5	54
9	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of Clinical Oncology, 2020, 38, 3743-3752.	1.6	50
10	ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. Scientific Reports, 2015, 5, 9170.	3.3	49
11	Clinical significance of monitoring <i>ESR1</i> mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget, 2016, 7, 32504-32518.	1.8	49
12	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. Breast Cancer, 2016, 23, 329-342.	2.9	49
13	Analysis of <i>ESR1</i> and <i>PIK3CA</i> mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget, 2017, 8, 52142-52155.	1.8	48
14	Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes?. Surgery, 2014, 155, 927-935.	1.9	45
15	Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2022, 40, 1002-1002.	1.6	44
16	Clinicopathological features and treatment strategy for triple-negative breast cancer. International Journal of Clinical Oncology, 2010, 15, 341-351.	2.2	41
17	Fibroblast growth factor receptorâ€1 protein expression is associated with prognosis in estrogen receptorâ€positive/human epidermal growth factor receptorâ€2â€negative primary breast cancer. Cancer Science, 2016, 107, 491-498.	3.9	40
18	Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Molecular Cancer, 2018, 17, 67.	19.2	40

#	ARTICLE	IF	CITATIONS
19	Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. Japanese Journal of Clinical Oncology, 2011, 41, 709-712.	1.3	38
20	Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. Atherosclerosis, 2017, 260, 116-120.	0.8	33
21	Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer, 2016, 16, 230.	2.6	30
22	Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer, 2020, 27, 803-809.	2.9	30
23	Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. Translational Oncology, 2017, 10, 766-771.	3.7	29
24	An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer. PLoS ONE, 2014, 9, e116054.	2.5	28
25	C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients. European Journal of Human Genetics, 2015, 23, 949-956.	2.8	25
26	Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. Breast Cancer Research and Treatment, 2018, 172, 353-362.	2.5	20
27	Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer. Chinese Clinical Oncology, 2020, 9, 31-31.	1.2	19
28	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open, 2019, 4, e000476.	4.5	17
29	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2021, 39, 2452-2462.	1.6	16
30	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. ESMO Open, 2018, 3, e000314.	4.5	15
31	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 162, 501-510.	2.5	13
32	Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. BMC Cancer, 2017, 17, 786.	2.6	13
33	Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer, 2010, 17, 254-260.	2.9	11
34	Factors involved in early lenvatinib dose reduction: a retrospective analysis. Medical Oncology, 2018, 35, 19.	2.5	9
35	Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer. Surgery Today, 2016, 46, 214-223.	1.5	8
36	Soluble Factors Involved in Cancer Cell-Macrophage Interaction Promote Breast Cancer Growth. Anticancer Research, 2021, 41, 4249-4258.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	3.9	8
38	Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 473-482.	2.5	7
39	Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. <i>Breast Cancer</i> , 2021, 28, 145-160.	2.9	7
40	Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 24-26.	1.0	6
41	A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 855-859.	1.3	6
42	BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. <i>Diagnostics</i> , 2020, 10, 119.	2.6	6
43	Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. <i>Breast Cancer</i> , 2022, 29, 1-8.	2.9	6
44	ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study. <i>Cancer Biomarkers</i> , 2018, 22, 345-350.	1.7	5
45	Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. <i>Breast Cancer</i> , 2019, 26, 535-543.	2.9	5
46	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). <i>Breast Cancer</i> , 2021, 28, 1023-1037.	2.9	5
47	Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 636-649.	10.7	5
48	Prospective observational trial of re-antiestrogen therapy after becoming resistant to ethinylestradiol treatment in hormone-dependent metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 161-161.	1.6	4
49	Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy. <i>SpringerPlus</i> , 2015, 4, 108.	1.2	3
50	Divisional role of quantitative HER2 testing in breast cancer. <i>Breast Cancer</i> , 2015, 22, 161-171.	2.9	3
51	Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report. <i>International Cancer Conference Journal</i> , 2016, 5, 202-205.	0.5	3
52	Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum. <i>Breast Cancer</i> , 2021, 28, 746-754.	2.9	3
53	Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. <i>Breast Cancer</i> , 2022, 29, 368-376.	2.9	3
54	Cardiac computed tomography-derived myocardial tissue characterization after anthracycline treatment. <i>ESC Heart Failure</i> , 2022, 9, 1792-1800.	3.1	3

#	ARTICLE	IF	CITATIONS
55	A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2020, 180, 715-724.	2.5	2
56	Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer. Chinese Clinical Oncology, 2020, 9, 30-30.	1.2	2
57	A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01.. Journal of Clinical Oncology, 2012, 30, 588-588.	1.6	2
58	Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. , 2021, , .		1
59	BRCAness and prognosis of triple-negative breast cancer patients treated with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, e12111-e12111.	1.6	1
60	Preface for special issue “Advances in treatment and care in metastatic breast cancer” Chinese Clinical Oncology, 2018, 7, 22-22.	1.2	1
61	Association of response to neoadjuvant chemotherapy (NAC) in premenopausal patients with hormone receptor-positive early breast cancer with chemotherapy-induced ovarian function suppression by NAC.. Journal of Clinical Oncology, 2012, 30, e11017-e11017.	1.6	1
62	Focused issue “Neoadjuvant/adjuvant treatment for early breast cancer” Chinese Clinical Oncology, 2020, 9, 26-26.	1.2	0
63	Mouse mammary gland reconstitution with extrinsic gene-transferred mammary epithelial cells in vitro and in vivo. Inflammation and Regeneration, 2008, 28, 181-188.	3.7	0
64	Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues.. Journal of Clinical Oncology, 2013, 31, 571-571.	1.6	0
65	N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS).. Journal of Clinical Oncology, 2013, 31, TPS654-TPS654.	1.6	0
66	Subsequent endocrine therapy after resistance to ethinylestradiol treatment for the late-stage metastatic breast cancer: A retrospective cohort study.. Journal of Clinical Oncology, 2014, 32, 148-148.	1.6	0
67	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. Journal of Clinical Oncology, 2016, 34, TPS636-TPS636.	1.6	0
68	Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan.. Annals of Cancer Research and Therapy, 2022, 30, 38-44.	0.3	0